Video

Dr. Lyou on Emerging Biomarkers in Prostate Cancer

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

Yung Lyou, MD, PhD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses emerging biomarkers in prostate cancer.

One advancement being made with regard to biomarkers is the uptake of liquid biopsies for men with prostate cancer, Lyou says. Rather than relying solely on invasive, tumor-based tissue testing, liquid biopsy offers a less invasive, blood-based option for genomic assessment, Lyou explains. 

Additionally, biomarkers such as soluble PD-L1 and FGFR3 are being evaluated for use with blood-based biopsies, Lyou says. Regarding tissue-based testing, stromal signature TFG-ß could offer a potentially actionable target in prostate cancer, concludes Lyou.

Related Videos
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Thomas Westbrook, MD, assistant professor, Rush University Medical Center
Kathleen N. Moore, MD, MS
Tanios Bekaii-Saab, MD, FACP
Deena Mary Atieh Graham, MD
 Rupesh Rajesh Kotecha, MD